SCHEMBL1156438

SCHEMBL1156438

O=S(=O)(Cl)c1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HTT P42858 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPK1 P28482 1/20 0.50
PTPRZ1 P23471 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KIF11 P52732 2/20 0.47
POLB P06746 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ESPL1 Q14674 1/20 0.41
EPAS1 Q99814 5/20 0.39
PIP4K2A P48426 1/20 0.39
OXTR P30559 1/20 0.37
NAMPT P43490 1/20 0.36
TEAD1 P28347 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713706 0.82 ALDH1A1 (0.44) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL1828426 0.81 ALDH1A1 (0.54) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL14533590 0.79 LMNA (0.48) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL651902 0.79 ALDH1A1 (0.71) LMNAALDH1A1MAPK1HSD17B10TDP1
SCHEMBL1156141 0.79 ALDH1A1 (0.48) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL7937243 0.78 ALDH1A1 (0.52) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL517720 0.78 ALDH1A1 (0.52) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL11685641 0.77 LMNA (0.47) LMNAALDH1A1HTTSMN1; SMN2MAPK1
SCHEMBL23044031 0.76 ALDH1A1 (0.61) LMNAALDH1A1SMN1; SMN2MAPK1HSD17B10
SCHEMBL1098294 0.76 LMNA (0.50) LMNAALDH1A1HTTSMN1; SMN2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2026-04-21 US disclosed
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO, INC. 2024-12-12 US disclosed
CN-118791407-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-10-18 CN disclosed
CN-118638096-A Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives 奥索生物公司 2024-09-13 CN disclosed
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives ORSOBIO, INC. (US) 2024-07-30 US disclosed
CN-112204008-B Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives 奥索生物公司 2024-07-05 CN disclosed
EP-3796975-B1 SULFONYLAMINOBENZAMIDE DERIVATIVES ORSOBIO INC (US) 2023-08-30 EP disclosed
US-20220315548-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 2022-10-06 US disclosed
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES GILEAD SCIENCES, INC. 2022-02-24 US disclosed
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives THE LIVER COMPANY INC. (US) 2021-10-05 US disclosed
US-20150322058-A1 Oxytocin receptor agonists for the treatment of CNS diseases HOFFMANN-LA ROCHE INC. (US) 2015-11-12 US disclosed
EP-2336107-B1 Proton pump inhibitors TAKEDA PHARMACEUTICAL (JP) 2015-09-23 EP disclosed
US-20140343070-A1 PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-11-20 US disclosed
WO-2014111356-A1 OXYTOCIN RECEPTOR AGONISTS FOR THE TREATMENT OF CNS DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2014-07-24 WO disclosed
EP-1803709-B1 PROTON PUMP INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2013-01-02 EP disclosed
US-8048909-B2 Proton pump inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-01 US disclosed
EP-2336107-A2 Proton pump inhibitors Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
US-20110028476-A1 PROTON PUMP INHIBITORS KAJINO MASAHIRO 2011-02-03 US disclosed
US-20080139639-A1 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-06-12 US disclosed
EP-1803709-A1 PROTON PUMP INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2007-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322058-A1 Oxytocin receptor agonists for the treatment of CNS diseases OXTR, CRHR1, AVPR2 LMNA 3514/4885ALDH1A1 831/4885HTT 1195/4885
US-20220315548-A1 SMALL MOLECULE AGONISTS OF MUCOLIPIN 1 AND USES THEREOF MCOLN1, MCOLN2, MCOLN3 LMNA 581/4885ALDH1A1 1368/4885HTT 1333/4885
US-20140343070-A1 PROTON PUMP INHIBITORS HRH2, HRH4, CYP2C19 LMNA 3729/4885ALDH1A1 2529/4885HTT 855/4885
US-20220055985-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B LMNA 3274/4885ALDH1A1 245/4885HTT 3379/4885
US-12049439-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B LMNA 3274/4885ALDH1A1 245/4885HTT 3379/4885
US-20080139639-A1 3-amino(alkyl)-substituted pyrrole compounds such as N-methyl-1-[1-(phenylsulfonyl)-5-(3-thienyl)-1H-pyrrol-3-yl]methanamine; peptic ulcer, Zollinger-Ellison syndrome, gastritis, gastroesophageal reflux disease, gastric cancer, ulcer caused by non-steroidal anti-inflammatory agent (NSAID) use PTGER1, PTGER3, NR3C1 LMNA 4165/4885ALDH1A1 1764/4885HTT 3098/4885
US-12606522-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives NR3C2, NR5A1, SRD5A2 LMNA 3522/4885ALDH1A1 1507/4885HTT 1304/4885
US-20240409508-A1 SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES STS, SULT2A1, SCN2B LMNA 3274/4885ALDH1A1 245/4885HTT 3379/4885
US-20110028476-A1 PROTON PUMP INHIBITORS HRH2, HRH4, CYP2C19 LMNA 3735/4885ALDH1A1 2505/4885HTT 863/4885
US-11136290-B2 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives STS, SULT2A1, SCN2B LMNA 3274/4885ALDH1A1 245/4885HTT 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.